
EME · NYSE
Consensus is Buy across all four analysts, with a reported mean price target of $918. Low and high targets are unavailable, so target clustering and the width of the spread cannot be measured. The evidence names no individual analysts or firms, meaning the most and least bullish analysts cannot be identified. It also supplies no explicit rating or target revisions during the past week, so the direction of revisions cannot be established. The substantive disagreement visible in the accompanying research is whether record backlog, AI-driven demand, acquisitions and raised guidance justify EMCOR’s premium valuation despite execution risks.